$PHIO
Phio Pharmaceuticals Corp.

2016 Q2 Form 10-Q Financial Statement

#000119312516588016 Filed on May 12, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2016 Q1 2015 Q1
Revenue $9.000K $10.00K $34.00K
YoY Change -70.59% 17.24%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $890.0K $950.0K $870.0K
YoY Change 11.25% 9.2% 3.57%
% of Gross Profit
Research & Development $1.339M $1.305M $2.107M
YoY Change -1.62% -38.06% 42.75%
% of Gross Profit
Depreciation & Amortization $20.00K $14.00K $21.00K
YoY Change 0.0% -33.33% -4.55%
% of Gross Profit
Operating Expenses $2.224M $2.255M $2.980M
YoY Change 2.73% -24.33% 28.5%
Operating Profit -$2.215M -$2.245M -$2.946M
YoY Change 2.31% -23.79% 28.65%
Interest Expense $4.000K $7.000K $1.000K
YoY Change 300.0% 600.0% -83.33%
% of Operating Profit
Other Income/Expense, Net $3.000K $14.00K $1.000K
YoY Change -400.0% 1300.0%
Pretax Income -$2.210M -$2.230M -$2.950M
YoY Change 1.84% -24.41% 29.39%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.212M -$2.231M -$2.945M
YoY Change 2.12% -24.24% 28.94%
Net Earnings / Revenue -24577.78% -22310.0% -8661.76%
Basic Earnings Per Share
Diluted Earnings Per Share -$221.0M -$223.0M -$724.5M
COMMON SHARES
Basic Shares Outstanding 6.535M shares 65.35M shares 31.22M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.830M $7.690M $6.580M
YoY Change -58.33% 16.87% -45.21%
Cash & Equivalents $3.832M $4.192M $6.580M
Short-Term Investments $2.000M $3.500M
Other Short-Term Assets $530.0K $320.0K $400.0K
YoY Change -31.17% -20.0% 42.86%
Inventory
Prepaid Expenses $477.0K $265.0K
Receivables
Other Receivables
Total Short-Term Assets $6.359M $8.007M $6.981M
YoY Change -56.9% 14.7% -43.18%
LONG-TERM ASSETS
Property, Plant & Equipment $135.0K $149.0K $170.0K
YoY Change -25.41% -12.35% 9.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $27.00K $18.00K $18.00K
YoY Change 50.0% 0.0% -10.0%
Total Long-Term Assets $162.0K $167.0K $188.0K
YoY Change -18.59% -11.17% 8.67%
TOTAL ASSETS
Total Short-Term Assets $6.359M $8.007M $6.981M
Total Long-Term Assets $162.0K $167.0K $188.0K
Total Assets $6.521M $8.174M $7.169M
YoY Change -56.39% 14.02% -42.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $297.0K $281.0K $459.0K
YoY Change -53.23% -38.78% 65.7%
Accrued Expenses $1.256M $940.0K $1.097M
YoY Change 5.81% -14.31% 7.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.553M $1.221M $1.556M
YoY Change -14.76% -21.53% 11.94%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.553M $1.221M $1.556M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.550M $1.220M $1.560M
YoY Change -14.84% -21.79% 12.23%
SHAREHOLDERS EQUITY
Retained Earnings -$61.55M -$59.34M -$49.83M
YoY Change 18.38% 19.08%
Common Stock $1.000K $1.000K $3.000K
YoY Change -83.33% -66.67% 200.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.968M $6.953M $2.528M
YoY Change
Total Liabilities & Shareholders Equity $6.521M $8.174M $7.169M
YoY Change -56.39% 14.02% -42.46%

Cashflow Statement

Concept 2016 Q2 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$2.212M -$2.231M -$2.945M
YoY Change 2.12% -24.24% 28.94%
Depreciation, Depletion And Amortization $20.00K $14.00K $21.00K
YoY Change 0.0% -33.33% -4.55%
Cash From Operating Activities -$1.860M -$2.930M -$1.970M
YoY Change 3.33% 48.73% -17.23%
INVESTING ACTIVITIES
Capital Expenditures $8.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $1.500M $2.000M
YoY Change -118.75%
Cash From Investing Activities $1.500M $2.000M -$10.00K
YoY Change -118.68% -20100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $64.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 60.00K
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -1.860M -2.930M -1.970M
Cash From Investing Activities 1.500M 2.000M -10.00K
Cash From Financing Activities 0.000 0.000 60.00K
Net Change In Cash -360.0K -930.0K -1.920M
YoY Change -38.98% -51.56% -19.33%
FREE CASH FLOW
Cash From Operating Activities -$1.860M -$2.930M -$1.970M
Capital Expenditures $8.000K
Free Cash Flow -$1.978M
YoY Change -16.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6534846 shares
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6580000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
389942 shares
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
26.40
CY2016Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6534846 shares
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
263231 shares
CY2016Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2556966 shares
CY2016Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6534846 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
32.50
CY2016Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
6953000
CY2016Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
66288000
CY2016Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
281000
CY2016Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
940000
CY2016Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2016Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18000
CY2016Q1 us-gaap Assets
Assets
8174000
CY2016Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59336000
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8174000
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1221000
CY2016Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
149000
CY2016Q1 us-gaap Assets Current
AssetsCurrent
8007000
CY2016Q1 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
3500000
CY2016Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
265000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4192000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8496000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
332376 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
30.50
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6534846 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6534846 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
8890000
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
65994000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1163000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1106000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57105000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11159000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2269000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18000
CY2015Q4 us-gaap Assets
Assets
11159000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
163000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
10978000
CY2015Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
5500000
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
311000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5117000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1972000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.32
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1065508 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9116 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0147 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.88
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0151 pure
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2376349 shares
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-2945000
CY2015Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3130000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-47000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.9029 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9010 pure
CY2015Q1 us-gaap Revenues
Revenues
34000
CY2015Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2946000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1000
CY2015Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-91000
CY2015Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
185000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
411000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1916000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
2980000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-8000
CY2015Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
228000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
64000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2107000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
95000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
873000
CY2015Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
3686000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
174000
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21000
CY2015Q1 rxii Nonemployee Share Based Compensation Expense Income
NonemployeeShareBasedCompensationExpenseIncome
16500
CY2015Q1 rxii Exchange Of Temporary To Permanent Equity
ExchangeOfTemporaryToPermanentEquity
2000000
CY2015Q1 rxii Dividends Paid Preferred Stock
DividendsPaidPreferredStock
105000
CY2016Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2925000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
CY2016Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016Q1 dei Amendment Flag
AmendmentFlag
false
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2946908 shares
CY2016Q1 dei Document Type
DocumentType
10-Q
CY2016Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001533040
CY2016Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.1670 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.92
CY2016Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 dei Entity Registrant Name
EntityRegistrantName
RXi Pharmaceuticals Corp
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
57566 shares
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0118 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.20
CY2016Q1 dei Document Period End Date
DocumentPeriodEndDate
2016-03-31
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0202 pure
CY2016Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.8864 pure
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Uses of Estimates in Preparation of Financial Statements</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p> </div>
CY2016Q1 dei Trading Symbol
TradingSymbol
RXII
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7942 pure
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6534846 shares
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-2231000
CY2016Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2231000
CY2016Q1 us-gaap Revenues
Revenues
10000
CY2016Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
7000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2245000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14000
CY2016Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-46000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
294000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-925000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
2255000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
2000000
CY2016Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
2000000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1305000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-166000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
950000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-882000
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14000
CY2016Q1 rxii Nonemployee Share Based Compensation Expense Income
NonemployeeShareBasedCompensationExpenseIncome
-1000

Files In Submission

Name View Source Status
0001193125-16-588016-index-headers.html Edgar Link pending
0001193125-16-588016-index.html Edgar Link pending
0001193125-16-588016.txt Edgar Link pending
0001193125-16-588016-xbrl.zip Edgar Link pending
d134499d10q.htm Edgar Link pending
d134499dex311.htm Edgar Link pending
d134499dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rxii-20160331.xml Edgar Link completed
rxii-20160331.xsd Edgar Link pending
rxii-20160331_cal.xml Edgar Link unprocessable
rxii-20160331_def.xml Edgar Link unprocessable
rxii-20160331_lab.xml Edgar Link unprocessable
rxii-20160331_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending